| Title |
Future prospects in the treatment of erectile dysfunction: focus on avanafil
|
|---|---|
| Published in |
Drug Design, Development and Therapy, October 2011
|
| DOI | 10.2147/dddt.s15852 |
| Pubmed ID | |
| Authors |
Amjad Alwaal, Raed Al-Mannie, Serge Carrier |
| Abstract |
The treatment of erectile dysfunction (ED) has been revolutionized in the last 15 years with the introduction of type 5 phosphodiesterase (PDE5) inhibitors. Their efficacy, safety, and ease of administration have made them first-line treatment for ED. This article reviews the current therapies available for ED, and the new PDE5 inhibitors that are being investigated. Furthermore, it examines all the current ED treatment options that are in different phases of development (including oral and topical pharmacotherapy, gene therapy, and tissue engineering). A special emphasis is on avanafil, a new PDE5 inhibitor that has been studied extensively in Phase I and II clinical trials and has undergone several Phase III trials. Avanafil is a promising medication for ED due to its favorable pharmacokinetics, safety, and efficacy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Egypt | 1 | 2% |
| Unknown | 53 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 19% |
| Professor > Associate Professor | 9 | 17% |
| Student > Bachelor | 8 | 15% |
| Researcher | 6 | 11% |
| Student > Ph. D. Student | 3 | 6% |
| Other | 7 | 13% |
| Unknown | 11 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 41% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 13% |
| Agricultural and Biological Sciences | 3 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Nursing and Health Professions | 2 | 4% |
| Other | 4 | 7% |
| Unknown | 14 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 January 2014.
All research outputs
#2,420,057
of 25,394,764 outputs
Outputs from Drug Design, Development and Therapy
#127
of 2,270 outputs
Outputs of similar age
#12,132
of 144,007 outputs
Outputs of similar age from Drug Design, Development and Therapy
#1
of 3 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,270 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 144,007 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them